Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment
NCT ID: NCT03139253
Last Updated: 2017-05-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
120 participants
INTERVENTIONAL
2017-05-30
2017-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment
NCT02988089
Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the First-line Helicobacter Pylori Eradication.
NCT03571230
Intraluminal Therapy for Helicobacter Pylori Infection
NCT03124420
Efficacy and Safety of 14-day Concomitant Therapy for Difficult-to-Treat Helicobacter Pylori Infection
NCT05126121
Intraluminal Metronidazole Powder Monotherapy for Helicobacter Pylori Infection
NCT03524833
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
clarithromycin susceptible
Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and clarithromycin.
Ilaprazole 5 mg b.i.d is used as the proton pump inhibitor (PPI).
amoxicillin
amoxicillin 1000 mg bid. for 14 days
clarithromycin
clarithromycin 500 mg bid. for 14 days.
Ilaprazole
Ilaprazole 5 mg bid. for 14 days.
metronidazole susceptible
Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and tinidazole.
amoxicillin
amoxicillin 1000 mg bid. for 14 days
tinidazole
tinidazole 500 mg bid. for 14 days.
Ilaprazole
Ilaprazole 5 mg bid. for 14 days.
levofloxacin susceptible
Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and levofloxacin.
amoxicillin
amoxicillin 1000 mg bid. for 14 days
levofloxacin
levofloxacin 500 mg qd. for 14 days.
Ilaprazole
Ilaprazole 5 mg bid. for 14 days.
furazolidone susceptible
Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and furazolidone.
amoxicillin
amoxicillin 1000 mg bid. for 14 days
furazolidone
furazolidone 100 mg bid. for 14 days.
Ilaprazole
Ilaprazole 5 mg bid. for 14 days.
tetracycline susceptible
Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and tetracycline.
amoxicillin
amoxicillin 1000 mg bid. for 14 days
tetracycline
tetracycline 750 mg bid. for 14 days.
Ilaprazole
Ilaprazole 5 mg bid. for 14 days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
amoxicillin
amoxicillin 1000 mg bid. for 14 days
clarithromycin
clarithromycin 500 mg bid. for 14 days.
tinidazole
tinidazole 500 mg bid. for 14 days.
levofloxacin
levofloxacin 500 mg qd. for 14 days.
furazolidone
furazolidone 100 mg bid. for 14 days.
tetracycline
tetracycline 750 mg bid. for 14 days.
Ilaprazole
Ilaprazole 5 mg bid. for 14 days.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients with gastrectomy, acute GI bleeding and advanced gastric cancer;
* Known or suspected allergy to study medications;
* Taking bismuth and antibiotics in the previous four weeks, or taking proton pump inhibitor and H2-receptor blockers in the previous two weeks;
* Currently pregnant or lactating
* Inability to provide informed consent and other situations that could interfere with the examination or therapeutic protocol.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yanqing Li
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yanqing Li
Vice president of Qilu Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Li Yanqing, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Qilu Hospital of Shandong University
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017SDU-QILU-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.